Abstract: Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.

Abstract: Disclosed herein are compositions and methods for treating and preventing neurodegenerative diseases, such as Alzheimer's disease. In some embodiments, the composition comprises a peptide that disrupts the binding between PTP? and APP, preventing ?-amyloidogenic processing of APP without affecting other major substrates of ?- and ?-secretases. Alternatively, in some embodiments, an antibody or a fragment of an antibody against PTP? or APP may be used to disrupt the binding between PTP? and APP. In some embodiments, the composition comprises compounds or enzymes, which restore perineuronal balance of PTP? ligands CS and HS, thereby preventing abnormally increased ?-amyloidogenic processing of APP. Compositions and methods disclosed herein can be used in combination to treat and prevent neurodegenerative diseases.

Abstract: The treatment of diastolic dysfunction in a subject and, in particular, compositions for use and methods in treating diastolic dysfunction are disclosed. In one aspect, the disclosure provides a composition for use comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular, the composition for use according to the disclosure comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.

Abstract: The present invention relates to a combination of abemaciclib and pembrolizumab and methods of using the combination to treat certain disorders, such as breast cancer and non-small cell lung cancer.

Abstract: A pharmaceutical composition for preventing or treating cartilage diseases, and pharmaceutical preparation that includes the pharmaceutical composition as an active ingredient are provided.

Abstract: Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.

Abstract: A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.

Abstract: Pharmaceutical formulations and pharmaceutical compositions comprising reverse PEGylated oxyntomodulin conjugates, and methods of producing, and using the same are described. Conjugates include those attaching a polyethylene glycol polymer (PEG polymer) and 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) to a oxyntomodulin peptide, wherein the PEG polymer is attached to the amino terminus or to an amino residue within the oxyntomodulin via a flexible linker, wherein the flexible linker comprises a Fmoc or a FMS.

Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.

Abstract: A method of treating hyperglycemia, diabetes, metabolic syndrome, insulin resistance (insulin insensitivity), impaired glucose tolerance, high glucose levels, pulmonary hypertension, and/or a condition arising from any of the foregoing in a patient is provided. The method comprises knocking down mARC2 or mARC1 expression in the patient, or otherwise decreasing mARC2 and mARC1 activity in the patient.

Abstract: The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration.

Abstract: The invention relates to the use of at least one acid stable protease in poultry feed in combination with anti-coccidial vaccination of birds for increasing the performance of vaccinated animals. It has been found surprisingly that the additions of at least one acid stable protease according to the invention to the diet of “cocci”-vaccinated birds have a significant improvement of animal performance. The inventors found that especially the use of serine proteases improve the performance of vaccinated broiler chickens, in particular, the use of serine proteases increases weight gain and improves Feed Conversion Ratio (FCR) of cocci-vaccinated birds.

Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.

Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficienty are disclosed.

Abstract: In one embodiment a vaccine composition comprises two or three AChR subunit constructs and an adjuvant. In some embodiments the AChR subunit construct is an AChR ?1 subunit construct, an AChR ?1 subunit construct, an AChR ? subunit construct, an AChR ? subunit construct, or an AChR ? subunit construct. In another embodiment, the invention provides a method of treating myasthenia gravis in a patient in need thereof, comprising administering a vaccine composition comprising one or more acetylcholine receptor subunit constructs selected from the group consisting of AChR ?1 subunit, AChR ?1 subunit, AChR ? subunit, AChR ? subunit, AChR ? subunit, a fragment thereof, and a combination thereof, and an adjuvant.

Abstract: This disclosure provides methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life. This disclosure also provides methods to construct activatable enzyme, which becomes active when they reach the treatment target, therefore provide higher specificity for treatment.

Abstract: The presently-disclosed subject matter includes a multivalent biological construct that comprises a scaffold of anisometric dimensions, comprises a biodegradable hydrophobic core coated with a hydrophilic coat of fluidic material, and pluralities of bioactive molecules tethered to said scaffold. The multivalent biologic construct interacts simultaneously with multiple corresponding binding sites, increasing the functional affinity to induce an augmented therapeutic action in the form of stimulation, activation, competitive inhibition, consumptive inhibition or modulation of a biological system. Embodiments of the presently-disclosed subject matter include methods for preparation of the present construct as well as methods for using the present constructs to overcome cellular resistance, as thrombolytics, as competitive inhibitors, as consumptive inhibitors, as vaccines and as immunomodulators to treat a subject in need thereof.

Abstract: A live attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpB protein and a method of using the same to protect fish against infection from virulent Edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent Edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional protein selected from the group consisting of evpB, fur and hfq. The bacterium may include an insertion and/or deletion mutation in the gene. The fish include catfish, preferably catfish fingerling or a catfish fry. The composition may be delivered via immersion delivery, an injection delivery, an oral delivery, or combinations thereof.

Abstract: The present invention provides a vaccine composition for use in neurodegenerative diseases and an infectious virus vaccine composition for inducing an antibody recognizing the conformation of antigens. The vaccine composition of the present invention induces the production of an antibody recognizing the conformation of antigens. The antibody recognizing the conformation of antigens has high specificity for an antigen, and thus can be useful for ameliorating, preventing or treating diseases.

Abstract: The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.

Abstract: The invention relates to nucleic acids, including lentiviral vectors and lentiviral vector particles, encoding at least one Hepatitis B virus (HBV) envelop surface of genotypes A and/or C antigen, at least one polymerase of genotypes A and/or C antigen, at least one HBX protein of genotypes A and/or C antigen, at least one HBV consensus core of genotypes A and/or C antigen, and at least one HBV consensus core MHCI and MHCII epitopes of genotypes A and/or C antigen. The invention encompasses these lentiviral vectors and lentiviral vector particles, methods of making the vectors, and their use, including medicinal uses. The lentiviral vectors and lentiviral vector particles are for use in administering to humans to induce immune responses against the HBV antigens.

Abstract: The present invention relates to a type I or II transmembrane fusion protein comprising, successively: a) optionally, a signal peptide; b) a protein or a peptide of interest; c) a coiled-coil domain; and d) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. It also relates to the virus-like particles obtained with this fusion protein.

Abstract: The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.

Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Abstract: A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.

Abstract: This disclosure provides cell surface anchoring conjugates, formulations comprising cell surface anchoring conjugates, TLR agonist and methods of using the same for boosting immunity in a subject and treating tumor cell and cancer.

Abstract: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Abstract: The present invention relates to a compound comprising one or more PEG moieties, wherein said compound is a therapeutic agent active for treating a respiratory disease. The present invention also relates to a method for preventing and/or treating a respiratory disease in a subject in need thereof comprising the administration of a PEGylated therapeutic agent. Another object of the invention is a method for enhancing the bioavailability of a therapeutic agent, for enhancing the pulmonary residency of a therapeutic agent and/or for reducing the pulmonary clearance of a therapeutic agent, wherein said methods comprise the PEGylation of the therapeutic agent.

Abstract: The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.

Abstract: Methods of treating patients suffering from cancer using a combination of 1) an immunomodulatory agent; 2) a check point inhibitor; and 3) a cancer antigen releasing therapy are provided. In some aspects, the immunomodulatory agent is an anti-CD3 immunotoxin, the check point inhibitor inhibits the interaction of PD-1 and PD-L1 and the cancer antigen releasing therapy is radiation.

Abstract: The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin expressing cells and to block the activation of MAPK in PDGF stimulated human pericytes. The antibody is able to block angiogenesis induced by LGALS3BP, a known Endosialin interactor and to inhibit tumor growth alone and in combination with 1959, a humanized antibody against LGALS3BP in human osteosarcoma xenograft. Furthermore, upon conjugation of the humanized version of the anti-Endosialin antibody with a duocarmycin derivative, the resulting ADC displays potent and antigen dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo. The disclosure is also related to nucleotides encoding the antibodies of the disclosure and cell expressing the antibodies.

Abstract: This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).

Abstract: Disclosed herein are nanodroplet compositions composed of a copolymer with a hydrophilic block and a hydrophobic block, a poloxamer, an oil, an anti¬cancer agent, and optionally a lyoprotectant. The nanodroplet compositions exhibit low toxicity and are biodegradable, provide for slow, sustained release of the anti-cancer agent at tumor sites, and result in a greater reduction of tumor volume when administered to subjects with cancer as compared to several commercially-available products. Furthermore, the nanodroplet compositions can be imaged and their progress through the body tracked with magnetic resonance spectroscopy or ultrasound.

Abstract: The present application describes compositions that can be used for the controlled release of pharmacological active ingredients from a viscoelastic aqueous polysaccharide matrix, and their potential use in the treatment of different stages of musculoskeletal diseases. The combination of drug release modulation and the viscoelastic nature of the composition makes possible the use thereof in the treatment of acute and chronic phases of musculoskeletal diseases characterized by an inflammatory state, and where a therapeutic effect and a viscosupplemental contribution are required.

Abstract: The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.

Abstract: A vector comprising a promoter operably linked to a nucleic acid sequence encoding human aldehyde dehydrogenase, as well as a composition comprising the vector and method of using the vector to treat aldehyde dehydrogenase deficiency, or to prevent or treat a disease characterized by aldehyde dehydrogenase deficiency.

Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue, suggesting favorable selective activity of compounds according to the present invention, which can be used as effective therapeutic agents against melanoma, including metastatic melanoma. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are useful to initiate therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic and therapeutic tools for a number of conditions and diseases states, especially melanoma.

Abstract: The present invention is directed to methods for providing a peptide receptor radiotherapy treatment recommendation for a subject having a neuroendocrine tumor by determining the expression level of each of at least 9 biomarkers comprising ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9. In some embodiments, the methods can further include determining the expression level of each of NAP1L1, NOL3, and TECPR2.

Abstract: Sanitizing surfaces in a location related to aircraft. There are multiple rows of seats. A sanitization device includes a mobile body configured to travel along the aisle of the aircraft. An arm extends from the sanitization device laterally from the mobile body across the seats, and a source of UV radiation mounted on the sanitization device is directed across the seats exposing surfaces in the passenger area to UV radiation. There is a data collector to collect information in the aircraft. A passive RFID tag mounted on elements can be read by an RFID reader. The device can include one or more sniffer cells for scanning the aircraft for unwanted or dangerous devices or chemicals.

Abstract: Systems and methods for sterilization using nonthermal plasma (NTP) ionization are disclosed. An example method for inactivation of viable microorganisms includes: inactivating viable microorganisms in a predetermined volume by: installing a plurality of ceiling mounted direct current (DC) or alternating current (AC), bipolar or steady-state, ion emitter modules based on a geometry of the predetermined volume; and producing, using the plurality of ceiling mounted ion emitter modules, a DC or AC, bipolar or steady-state, nonthermal plasma (NTP), each of the ceiling mounted ion emitter modules comprising a high voltage power supply (HVPS).

Abstract: Method of calculating an exposure time for disinfecting a room using an ultraviolet disinfecting apparatus comprises the steps of measuring distances by: using a spatial sensor on the ultraviolet disinfecting apparatus, to perform a first scan of a boundary surface of the room, to measure a first set of distances from the sensor to the boundary surface; adjusting the height or orientation of the spatial sensor; using the spatial sensor to perform a second scan of the boundary surface of the room, to measure a second set of distances from the adjusted sensor to the boundary surface; and subsequently, calculating the exposure time in dependence the sets of distances.

Abstract: The safe incense evaporator has a bowl, a flat lid covering the bowl, and a cap or dome defining a chamber above the lid. The bowl defines a basin, and a crucible is concentrically seated at the top of the basin. The basin allows water to surround the crucible. Very small orifices are defined in a central area of the lid, and are also defined in the dome to allow the scent of burning incense to leave the evaporator. The crucible is adapted for holding incense coal or charcoal used to burn or heat incense. The evaporator may have a latch holding the cap onto the bowl in case the evaporator tips over onto its side so that the coals or charcoal will be extinguished by the water from the basin. The evaporator may also have a dual latch or lock to prevent children from tampering with the evaporator.

Abstract: A constructive arrangement introduced into fan having volatilizing function of repellent substance in a strip. The arrangement has a strip containing a substance to be dispersed into the environment is disposed at the front part of the supporting column of the fan, beneath the perimeter of its propellers, creating a pressure difference which provides for the propagation of the dispersion of the substance into the environment, and where the supporting column of the fan, besides acting as a barrier against air flows produced in the environment, preventing the dilution of the volatilized mist, will also enable the enclosure of the electrical wires used in the connections, making energizing the volatilizing combination much easier, more practical and economical.